These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34909720)

  • 61. Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry.
    Wu JJ; Harrison RW; Zhu B; Goldblum OM; Malatestinic WN; Burge R; Murage MJ
    J Comp Eff Res; 2021 Feb; 10(2):157-167. PubMed ID: 33355477
    [No Abstract]   [Full Text] [Related]  

  • 62. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
    Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
    Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
    Jacobson CC; Kimball AB
    Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
    Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
    Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.
    Papp KA; Gooderham M; Beecker J; Lynde CW; Delorme I; Dei-Cas I; Albrecht L; Rampakakis E; Sampalis JS; Vieira A; Hussein S; Chambenoit O; Rihakova L
    BMC Dermatol; 2019 Jun; 19(1):9. PubMed ID: 31226985
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
    Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
    Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.
    No DJ; Amin M; Bhutani T; Wu JJ
    J Dermatolog Treat; 2018 Aug; 29(5):467-474. PubMed ID: 29103334
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.
    Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
    Clin Rheumatol; 2017 Apr; 36(4):895-901. PubMed ID: 28271234
    [TBL] [Abstract][Full Text] [Related]  

  • 69. -174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers.
    Di Renzo L; Bianchi A; Saraceno R; Calabrese V; Cornelius C; Iacopino L; Chimenti S; De Lorenzo A
    Pharmacogenet Genomics; 2012 Feb; 22(2):134-42. PubMed ID: 22158445
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
    Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
    JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
    Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
    Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population.
    Augustin M; Dauden E; Mrowietz U; Konstantinou MP; Gerdes S; Rissler M; Gathmann S; Sieder C; Baeumer D; Orsenigo R
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2548-2556. PubMed ID: 32239541
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
    Bożek A; Reich A
    Adv Clin Exp Med; 2017 Aug; 26(5):851-856. PubMed ID: 29068583
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
    Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
    Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Establishment of the Western Japan Psoriasis Registry and first cross-sectional analysis of registered patients.
    Tsuruta N; Imafuku S;
    J Dermatol; 2021 Nov; 48(11):1709-1718. PubMed ID: 34427347
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
    Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
    Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Geographic Patterns in Psoriasis: An Observational Study of CorEvitas Psoriasis Registry.
    Enos CW; O'Connell KA; Harrison RW; McLean RR; Dube B; Van Voorhees AS
    J Psoriasis Psoriatic Arthritis; 2022 Jul; 7(3):122-131. PubMed ID: 39296532
    [No Abstract]   [Full Text] [Related]  

  • 78. Geographic Disparities in Online Searches for Psoriasis Biologics in the United States: Google Trends Analysis.
    Chang A; O'Hagan R; Young JN; Wei N; Gulati N
    JMIR Dermatol; 2024 Jul; 7():e56406. PubMed ID: 39083767
    [No Abstract]   [Full Text] [Related]  

  • 79. The Effects of Cardiometabolic Comorbidities on Biologic Treatment for Psoriasis with Respect to PASI Scores: A Qualitative Systematic Review.
    Osman A; Nigro A; Taylor AC; Saal R; Ormaza Vera A; Enos C
    Psoriasis (Auckl); 2024; 14():1-10. PubMed ID: 38226336
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of Season and Other Factors on Initiation, Discontinuation, and Switching of Systemic Drug Therapy in Patients with Psoriasis: A Retrospective Study.
    Liang H; Kirk B; Polinski JM; Yue X; Kilpatrick RD; Gelfand JM
    JID Innov; 2023 Mar; 3(2):100171. PubMed ID: 36876219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.